JNJ Under Scrutiny for AI Surgical Tool Failures; Also Advancing Serotonergic Therapies

J&J Faces Scrutiny Over AI-Assisted Surgical Tool

Acclarent, a Johnson & Johnson subsidiary, is facing renewed scrutiny after a Reuters investigation finds widespread reports of technical failures and patient injuries tied to its TruDi Navigation System. The system, updated in 2021 with machine‑learning software to help ENT surgeons guide instruments during sinus procedures, is linked in federal reports to more than 100 incidents and at least 10 patients harmed between late 2021 and 2025, according to the investigation. Several patients are suing, alleging the system provided incorrect location information that led to severe injuries including leaking spinal fluid, punctured skull bases and strokes.

The company and its distributors reject any causal link, telling Reuters there is “no credible evidence” that the AI update caused the harms. Court records, however, disclose disputes over surgeon ties to Acclarent and allegations that the product was rushed to market with acceptance of limited accuracy for some features. Plaintiffs in illustrative cases, such as Erin Ralph and Donna Fernihough, allege the navigation system misdirected surgeons and directly contributed to their injuries, while Acclarent maintains surgeons bear primary responsibility for device use.

The case highlights broader regulatory and safety challenges as artificial intelligence rapidly permeates medical devices. By 2025 the FDA has authorized more than 1,300 AI‑enabled devices, roughly double the number from a few years earlier, and Reuters’ review finds recall rates for AI products about twice that of similar non‑AI technologies. For Johnson & Johnson, the controversy raises reputational, legal and oversight questions as the company balances innovation with post‑market surveillance and clinician training amid growing regulatory attention.

Novel Serotonergic Therapies Gain Industry Focus

Separately, Johnson & Johnson appears among major pharma firms developing novel serotonergic agonists (NSAs) that target specific serotonin receptors to deliver faster relief for depression, PTSD, anxiety and addiction. The class is attracting industry partnerships and acquisition interest because a successful NSA platform can be applied across multiple neuropsychiatric indications and address a market estimated at $50–60 billion for depression and anxiety.

Regulatory Environment and Industry Implications

The Reuters reporting underscores a pattern for AI devices: rapid adoption followed by concentrated post‑market problems and lawsuits, prompting calls for stricter oversight and clearer FDA pathways. For J&J and peers, the twin pressures of advancing digital tools and expanding CNS franchises require intensified risk management and transparent clinical validation to sustain patient safety and public trust.